Industrial Purity Standards For R-5-Hydroxymethyl Tolterodine
- Critical Specification: HPLC assay must exceed 98.0% with strict enantiomeric excess controls for Fesoterodine synthesis.
- Analytical Validation: Requires comprehensive characterization via Chiral HPLC, NMR, and Mass Spectrometry to verify structure.
- Supply Chain Integrity: Sourcing from a certified global manufacturer ensures consistent COA documentation and regulatory compliance.
In the pharmaceutical manufacturing sector, the quality of chiral intermediates dictates the safety and efficacy of the final Active Pharmaceutical Ingredient (API). (R)-5-Hydroxymethyl Tolterodine serves as a critical metabolite and key intermediate in the synthesis of Fesoterodine Fumarate, a muscarinic receptor antagonist used to treat overactive bladder. Ensuring the chemical integrity of this compound is paramount, as impurities can propagate through the synthesis route, complicating purification steps and jeopardizing regulatory approval.
Procurement teams and quality assurance officers must adhere to stringent specifications when evaluating suppliers. The chemical identity, often referenced by its systematic name (R)-2-(3-(Diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol, requires precise stereochemical control. Deviations in enantiomeric purity can lead to the formation of diastereomers that are difficult to separate in downstream processing. Therefore, establishing robust quality benchmarks is essential for maintaining production efficiency and compliance with pharmacopeial standards.
Defining High Purity: HPLC Assay and Enantiomeric Excess
The primary metric for assessing the quality of this intermediate is the chemical assay, typically determined by High-Performance Liquid Chromatography (HPLC). For commercial-scale production, the target assay should be ≥98.0%. However, chemical purity alone is insufficient for chiral molecules. The enantiomeric excess (ee) must be rigorously monitored to ensure the predominance of the (R)-enantiomer over the (S)-enantiomer. High levels of the wrong enantiomer can act as a competitive inhibitor or introduce toxicological risks in the final drug product.
When evaluating industrial purity specifications, buyers should request detailed chromatograms that demonstrate the separation of closely related impurities. Common impurities include des-isopropyl variants and oxidation products of the phenol moiety. A reliable supplier will provide data on known related substances, ensuring that no single impurity exceeds 0.10% and total impurities remain below 0.50%. This level of control minimizes the burden on the API manufacturer during crystallization and purification stages.
Analytical Validation Methods
Verification of the molecular structure goes beyond simple chromatography. Comprehensive analytical validation involves a multi-instrument approach to confirm identity and purity. Nuclear Magnetic Resonance (NMR) spectroscopy is utilized to verify the proton and carbon environments, ensuring the hydroxymethyl group and the diisopropylamine side chain are correctly positioned. Mass Spectrometry (MS) provides confirmation of the molecular weight, typically observed at 341.49 g/mol for the free base.
Chiral HPLC is the gold standard for determining optical purity. Methods often utilize chiral stationary phases capable of resolving the (R) and (S) enantiomers with a resolution factor (Rs) greater than 2.0. Additionally, specific rotation measurements provide a quick reference for batch consistency. A comprehensive Certificate of Analysis (COA) should include data from all these methods, offering transparency into the manufacturing quality. This documentation is vital for regulatory filings, such as Drug Master Files (DMF) or Abbreviated New Drug Applications (ANDA).
Impact of Impurities on Fesoterodine Fumarate API Synthesis
The presence of impurities in the intermediate stage can have cascading effects on the final API. In the conversion to Fesoterodine Fumarate, reactive functional groups such as the phenol and the hydroxymethyl group are susceptible to further substitution or esterification. If the starting material contains reactive impurities, they may consume reagents, lower overall reaction yields, or generate hard-to-remove byproducts. For instance, oxidative impurities on the phenol ring can lead to colored residues that affect the appearance of the final API.
Furthermore, regulatory agencies require thorough characterization of impurities above certain thresholds. Using an intermediate with poorly defined impurity profiles can trigger additional toxicological studies, delaying time-to-market. Therefore, partnering with a global manufacturer who understands these downstream implications is crucial. They must employ robust process controls to minimize the formation of genotoxic impurities and ensure batch-to-batch consistency.
Technical Specifications and Storage Requirements
Physical handling and storage are also critical components of maintaining quality. The compound typically appears as an off-white to pale yellow solid. Due to the presence of the phenolic hydroxyl group, the material is sensitive to oxidation and light exposure. Standard storage conditions recommend maintaining the material at 2-8°C in a refrigerator, protected from light and moisture. Shipping conditions may vary, but ambient shipping is often acceptable for short durations if the packaging is sufficiently inert and sealed.
The following table outlines the standard technical specifications expected for high-grade pharmaceutical intermediates of this nature:
| Parameter | Specification | Test Method |
|---|---|---|
| Chemical Name | (R)-5-Hydroxymethyl Tolterodine | - |
| CAS Registry Number | 207679-81-0 | - |
| Molecular Formula | C22H31NO2 | - |
| Molecular Weight | 341.49 g/mol | - |
| Appearance | Off-White to Pale Yellow Solid | Visual |
| Assay (HPLC) | ≥ 98.0% | HPLC Area Normalization |
| Enantiomeric Excess | ≥ 99.0% | Chiral HPLC |
| Single Impurity | ≤ 0.10% | HPLC |
| Storage Temperature | 2-8°C | - |
Procurement and Manufacturing Excellence
Securing a reliable supply chain for chiral intermediates requires a partner with advanced synthetic capabilities. NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier entity in this space, offering specialized production capabilities for complex pharmaceutical intermediates. Their focus on process optimization ensures that the manufacturing process yields high consistency while managing costs effectively. For large-scale projects, understanding the bulk price dynamics is essential, and established manufacturers can offer competitive rates without compromising on quality standards.
In conclusion, the successful production of Fesoterodine relies heavily on the quality of its precursors. By enforcing strict analytical controls and sourcing from verified suppliers like NINGBO INNO PHARMCHEM CO.,LTD., pharmaceutical companies can mitigate risks associated with impurity profiles and regulatory compliance. Prioritizing high-purity intermediates ensures a smoother path through clinical trials and commercial manufacturing, ultimately delivering safer medications to patients.